Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Antiviral — RNA Polymerase Inhibitor (COVID-19 / Hepatitis)

Remdesivir

Brand names: Veklury

Remdesivir is a broad-spectrum antiviral nucleotide prodrug used for treatment of COVID-19 in eligible patients.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Its active metabolite acts as an analogue of adenosine triphosphate and inhibits the viral RNA-dependent RNA polymerase, causing premature termination of viral RNA synthesis.

Prescribing in practice

  • Hypersensitivity and infusion-related reactions, including anaphylaxis, can occur, so administer with appropriate monitoring and the ability to slow or stop the infusion.
  • Transient elevations in hepatic transaminases are common; assess liver function before and during treatment.
  • It is given by intravenous infusion only and should be reserved for patients meeting national eligibility criteria.

Monitoring

Monitor liver function tests and renal function before and during treatment, and observe for infusion reactions during administration.

Counselling the patient

  • This medicine is given as a drip in hospital or a monitored setting.
  • Report any rash, breathlessness or feeling faint during the infusion immediately.
  • Blood tests will be done to check your liver during treatment.

Evidence & guidelines

Remdesivir is recommended for selected COVID-19 patients in MHRA-authorised indications and NICE guidance.

Reference: Beigel et al. NEJM 2020 (ACTT-1); WHO SOLIDARITY trial 2021; NICE TA689; MHRA SPC Veklury; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways